Untranslated

More Language

86-2164556180

cpd-service@caerulumpharma.com

Home
De Us
Products
Solutions
Resources
- Downloadable
- Imago gallery
FAQs
Contact Us

Home
Products
Bioactive moleculis
Antineoplastic
Nrf2

Categories Products

Antineoplastic
- ACC
- Adenosine A2A
- ALK
- Androgen receptor inhibitor
- Apoptosis incitamentum
- ATR
- AXL
- BCl2-BH4
- Bcr-Abl
- BRAF
- BTK
- CDK
- Chk1
- CYP17
- DNA alkylating agente
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- IDO
- IRA
- LOCULUS
- LXR
- MDM2
- MEK
- MET
- Nrf2
- P90RSK
- P97
- PAKS
- PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Hypoglycemic medicinae
- DPP-4
- SGLT-1
- SGLT-2
alii
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAC
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- mACHRs
- NF-κB
- NRTI
- PPAR
- RIP1
- S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Nrf2

CAT #	Product Name	Descriptio
CPD1598	CDDO-Im
CPD1599	CDDO-3-P-Im
CPD1589	CDDO-2-P-Im

Contact Us

N. 401, 4th Solum, Aedificium 6, Quwu Road DLXXXIX, Minhang District, 200241 Shanghai, China
86-2164556180
In Sinis:
sales-cpd@caerulumpharma.com
International:
cpd-service@caerulumpharma.com

Inquisitionis

Percontationes de fructibus nostris, quaeso, electronicam tuam nobiscum relinque et intra 24 horas continuabimus.Inquisitionis

Tardus News

AstraZeneca moderantibus boost pro oncology medicinae accipit

AstraZeneca regulatory suscipit boost pro...

AstraZeneca duplicem boostem pro sua oncologia portfolio accepit die Martis, postquam US et moderatores Europaei subiectiones moderantes pro suis medicamentis acceperunt, primus gradus ad haec medicamenta approbavit. ...

Top VII trends in pharmaceutical Research in MMXVIII "

Top VII Trends in pharmaceutical Research I...

Cum semper ingravescentibus pressionibus certare in ambitu oeconomico et technologico, societatibus pharmaceuticis et biotechicis, semper innovare debent in R&D programmatis suis ut antecedant ...

ARS-1620.

ARS-1620.

Secundum studium editum in Cell, investigatores inhibitorem specificum pro KRASG12C ARS-1602 elaboraverunt quod regressionem tumoris in muribus induxerunt. "Hoc studium vivo testimonio praebet quod mutant KRAS potest esse...

AstraZeneca moderantibus boost pro oncology medicinae accipit

AstraZeneca regulatory suscipit boost pro...

AstraZeneca duplicem boostem pro sua oncologia portfolio accepit die Martis, postquam US et moderatores Europaei subiectiones moderantes pro suis medicamentis acceperunt, primus gradus ad haec medicamenta approbavit. ...

Top VII trends in pharmaceutical Research in MMXVIII "

Top VII Trends in pharmaceutical Research I...

Cum semper ingravescentibus pressionibus certare in ambitu oeconomico et technologico, societatibus pharmaceuticis et biotechicis, semper innovare debent in R&D programmatis suis ut antecedant ...

prev

next

© Copyright - 2015-2022 : All Rights Reserved.

FAQs
Downloadable
Contact Us

QR code

Whatsapp Online Chat!

TOP

Previous Maximize